In its long-awaited landmark decision in the case of Association
for Molecular Pathology v. Myriad Genetics Inc., the U.S.
Supreme Court has unanimously held that naturally occurring DNA
sequences are products of nature and not patent eligible merely
because they have been isolated. However, the Court also found that
artificially created DNA sequences, such as cDNA, are eligible for
patent protection because they do not occur naturally.
The Court's decision can be found at the following
link:
http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf.
The decision represents a compromise position that was proposed
during oral arguments in April 2013 by the Department of Justice
Solicitor General, Donald Verrilli, Jr. and effectively takes the
U.S. out of line with the current laws in relation to gene patents
that currently exist in Europe and Australia.